stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) EV/Sales
As of 5 November 2026, Spyre Therapeutics, Inc. (SYRE) trades at a EV/Sales of 7,143×. Over the past ten years it has ranged from −158× (July 2023) to 7,669× (August 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −3.1× | — |
| FY2022 | −8.7× | — |
| FY2021 | 10.4× | (15.49%) |
| FY2018 | 12.3× | 105.63% |
| FY2017 | 6.0× | — |
| FY2016 | −4.1× | — |
| FY2015 | −3.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | −3.1× | — |
| Jun 2023 | −157× | — |
| Mar 2023 | −9.6× | — |
| Dec 2022 | −8.7× | — |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CAI Caris Life Sciences,�Inc. compare | 6.8× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 7.8× |
| TGTX TG Therapeutics, Inc. compare | 10.5× |
| KRYS Krystal Biotech, Inc. compare | 17.0× |
| TWST Twist Bioscience Corporation compare | 17.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 28.9× |
| IBRX ImmunityBio, Inc. compare | 56.5× |
| CYTK Cytokinetics, Incorporated compare | 65.9× |
| SYRE Spyre Therapeutics, Inc. | 7,143× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement